Ocular DiscomfortNCT03031327
Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.
A study testing Lubricin 20µg/ml, Lubricin 50µg/ml and Sodium hyaluronate 0.18% in people with Ocular Discomfort, run by Dompé Farmaceutici S.p.A at 1 site in Italy.
Trial summary
The objective of this study was to evaluate tolerability, safety, permanence on the ocular surface and efficacy of Lubricin (20 and 50 μg/mL) eye drops vs Sodium Hyaluronate (Vismed®) 0.18% eye drops in patients with ocular discomfort following refractive surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ocular Discomfort
- What is being tested?
- Lubricin 20µg/ml, Lubricin 50µg/ml and Sodium hyaluronate 0.18%
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 17 Jun 2017to 10 Aug 2017
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients 18 years of age or older;
- Patients undergone ocular refractive surgery within 6 months from V1 - Day 1;
- Patients with ocular discomfort defined as SANDE score ≥ 30 at baseline;
- Average VAS score (dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia) ≥ 25 mm;
- Best corrected distance visual acuity (BCDVA) score ≥ 0.1 decimal units in both eyes at the time of study enrolment;
- Only patients who satisfy all Informed Consent requirements may be included in the study. The patient and/or his/her legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by patients and/or legal representative must have been approved by the Ethics Committee for the current study.
Who cannot join
- Patients with a severe Dry Eye condition (severity level 4 according to the Report of the International Dry Eye Workshop -DEWS, 2007);
- Best corrected distance visual acuity (BCDVA) score of < 0.1 decimal units in either eye at the time of study enrolment;
- Evidence of an active ocular infection in either eye;
- History or presence of ocular surface disorders other than ocular discomfort in either eye;
- Use of any ocular topical medication other than the study medications for the treatment of ocular diseases including artificial tears during the study period;
- Use of topical cyclosporine, topical corticosteroids or any other topical medication for the treatment of dry eye in either eye within 30 days of study enrolment;
Show all 16Show fewer
- History of any ocular surgery (excluding laser or refractive surgical procedures) in either eye within 30 days before study enrolment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period;
- Known hypersensitivity to one of the components of the study or procedural medications;
- Participation in another clinical study at the same time as the present study or within 90 days of screening/baseline visit;
- History of drug, medication or alcohol abuse or addiction;
- Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
- are currently pregnant or,
- have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
- intend to become pregnant during the study treatment period or,
- are breast-feeding or,
- not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD (intrauterine device ) during the entire course of and 30 days after the study treatment periods.
Trial locations and contacts
1 site in 1 country.
Italy1 site
Dipartimento "Organi di senso" Università La Sapienza- Policlinico Umberto I
Rome, 00161
About this study
Official title: A 2 Weeks, Randomized, Double-masked, Controlled Study to Assess Tolerability, Safety, Permanence on the Ocular Surface, Efficacy of Lubricin (20 and 50 μg/ml) vs Sodium Hyaluronate 0.18% in Ocular Discomfort Following Refractive Surgery.
The objective of this study was to evaluate tolerability, safety, permanence on the ocular surface and efficacy of Lubricin (20 and 50 μg/mL) eye drops vs Sodium Hyaluronate (Vismed®) 0.18% eye drops in patients with ocular discomfort following refractive surgery.
Primary objectives:
Read more
- Tolerability using a Visual analogue scale (VAS) for dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia;
- Treatment-emergent adverse events (TEAEs), assessed throughout the study.
Secondary objectives:
- Ocular surface vital staining with Fluorescein (Oxford scale)
- Schirmer-I test (without anaesthesia);
- Permanence of Lubricin on the Ocular Surface Tear film break-up time (TFBUT);
- Best corrected distance visual acuity (BCDVA);
- SANDE questionnaire scores - discomfort improvement entity;
- SANDE questionnaire scores - discomfort improvement speed;
- Signs evaluated by Slit lamp examination (SLE) (blepharitis, eyelid hyperemia/oedema, lashes, conjunctiva hyperemia);
- Intraocular pressure (IOP) ;
- Corneal sensitivity by Cochet-Bonnet aesthesiometry.
All parameters were evaluated at V1 (Day 1 - Baseline), V2 (Day 15±2) and V3 (Day 22±2/ETV).
Read the detailed description
This study was a 2 week randomized (1:1:1), controlled, double-masked, parallel group, pre-market study to evaluate tolerability, safety, permanence on the ocular surface and efficacy of Lubricin (20 and 50 μg/mL) eye drops vs Sodium Hyaluronate (Vismed®) 0.18% eye drops in patients with ocular discomfort following refractive surgery.
- Conditions
- Ocular Discomfort
- Being tested
- Lubricin 20µg/ml, Lubricin 50µg/ml, Sodium hyaluronate 0.18%
- Keywords
- Ocular Discomfort Following Refractive Surgery, Refractive Surgery, sodium hyaluronate, HA, Vismed®, Lubricin
- Medical subject headings
- Jacobs syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lubricin 20µg/mlDevice
Lubricin 20µg/ml eye drops
Lubricin 50µg/mlDevice
Lubricin 50µg/ml eye drops
Sodium hyaluronate 0.18%Device
Also called Vismed®
Sodium hyaluronate (HA) 0.18% eye drops
| Study group | Role | What they receive |
|---|---|---|
| Lubricin 20µg/ml | Experimental | Lubricin 20µg/ml eye drops solution
Test investigational device was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2.
All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the "Study/Primary eye". If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as "Study/Primary eye". In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as "Study/Primary eye".
The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable.
After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2. Receives: Device: Lubricin 20µg/ml |
| Lubricin 50µg/ml | Experimental | Lubricin 50µg/ml eye drops solution
Test investigational device was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2.
All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the "Study/Primary eye". If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as "Study/Primary eye". In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as "Study/Primary eye".
The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable.
After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2. Receives: Device: Lubricin 50µg/ml |
| Sodium hyaluronate | Active comparator | Vismed® 0.18% Sodium hyaluronate (HA) eye drops
Comparator was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2.
All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the "Study/Primary eye". If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as "Study/Primary eye". In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as "Study/Primary eye".
The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable.
After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2. Receives: Device: Sodium hyaluronate 0.18% |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes From Baseline (Day 1 Pre-dose) in Ocular Tolerability Using a Visual Analogue Scale (VAS)
A global ocular tolerability score was determined using a 100 mm Visual Analogue Scale (VAS) on which 0 meant no symptoms and 100 meant the worst possible discomfort. This evaluation was to be performed before any ophtalmic assessment at each scheduled visit. Specific ocular symptoms measured with the VAS included: foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia. The patients evaluated their symptoms using the VAS giving the value they were feeling from none to an extreme value. The VAS scale was a straight horizontal line of fixed length (100 mm). The ends were defined as extreme limits of the parameter.
Measured: Day 1 (baseline = Visit 1) at pre-dose, 15, 30 min post-dose; Day 15±2 (= Visit 2) at pre-dose, 15, 30 min post-dose; Day 22±2 (= Visit 3)
Treatment-emergent Adverse Events (TEAEs) Assessed Throughout the Study
TEAEs included all AEs occurring or worsening after the first dose of IMD. These comprise AEs during the treatment and follow-up period. For TEAE, the number of events was provided.
At each visit (Visit 1 which took place at Day 1; Visit 2 which took place at day 15 ± 2; Visit 3, i.e. final visi FU, at Day 22 ± 2/ETV), patients could spontaneously report any physical or medical occurrence and the investigator or designee inquired about the occurrence of TEAEs by asking specific questions. Any untoward (unfavorable \& unintended) change in subject's medical conditions was to be reported as an AE. Changes in any protocol-specific ocular or systemic parameter evaluated during the study were to be reviewed by the investigator. In addition, each patient's response to any questionnaire was to be reviewed by the investigator. Any untoward (unfavorable and unintended) change in a protocol-specific parameter or questionnaire response clinically relevant was to be reported as an AE.
Measured: From baseline (Day 1 - pre-dose) to day 22±2
Secondary outcomes (8)
Change From Baseline in Ocular Surface Vital Staining With Fluorescein (Oxford Scale)
The corneal fluorescein staining was graded by using the Oxford scheme to assess cornea and conjunctiva epithelium damage. It was performed after instillation of sodium fluoresce into the inferior conjunctival cul-de-sac of each eye with the aid of a slit lamp at 10X magnification using cobalt blue illumination.
The Oxford scale grading divides corneal staining into six groups for each panel, based on the severity [from 0 (absent) to 5 (severe)]. The corneal staining is represented by punctate dots on a series of panels (panel A=grade 0 to panel >E=grade 5). Staining ranges from 0-5 for each panel, and 0-15 for the total exposed inter-palpebral conjunctiva and cornea.
The examiner selected the appropriate grade that best represented the state of corneal staining intuitional. The higher the grade, the worst is the overall outcome value.
Measured: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Schirmer-I Test (Without Anaesthesia)
The Schirmer test Type I (without anaesthesia) was performed to measure aqueous tear secretion prior to the instillation of any dilating or anaesthetic eye drops. The rounded bent end of a sterile strip was inserted into the lower conjunctival sac over the temporal one-third of the lower eyelid margin. After 5 minutes had elapsed, the Schirmer's test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). The longer the wetted length, the healthier the status of the eye.
Measured: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Permanence of Lubricin on the Ocular Surface - Tear Film Break-up Time (TFBUT)
TFBUT was measured by determining the time to tear break-up. The TFBUT test was performed after instillation of 5 μl of 2% preservative-free sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. With the aid of a slit lamp at 10X magnification using cobalt blue illumination, the examiner monitored the integrity of the tear film, noting the time it took to form lacunae (clear spaces in the tear film) from the time that the eye was opened after the last blink. This measurement was performed within 10 seconds maximum. The TFBUT was measured twice during the first minute after the instillation of the fluorescein. If the 2 readings differed by more than 2 seconds, a third reading was taken. The TFBUT value was the average of the 2 or 3 measurements. Generally, a TFBUT value of 10-35 seconds was considered normal. A value of less than 10 seconds was usually suspicious and may indicate tear film instability. The higher the value, the better the outcome.
Measured: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA) - ETDRS Score
Best corrected visual acuity (BCDVA) was determined by careful refraction according to the standard protocol for refraction. Chart 1 was used for testing the VA of the right eye; Chart 2 for the left eye; and Chart R for refraction only. Retroilluminated standard Early Treatment of Diabetic Retinopathy Study (ETDRS) charts were used. They had 5 Sloan letters on each line of equal difficulty, and there was a geometric progression in letter size from line to line. VAS awarded one point for every letter correctly guessed. A distance of 4 meters was required between the subject's eyes and the VA chart. When a subject cannot read at least 20 letters on the chart at 4 meters, the subject was tested at 1 meter. If 20 or more letters were read at 4 meters, the VAS for that eye was recorded as the number of letters correct at 4 meters plus 30. Otherwise, the VAS was the number of letters read correctly at 1 meter plus the number read at 4 meters. The higher the score the better the outcome.
Measured: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in SANDE (Symptom Assessment in Dry Eye) Questionnaire Scores
The SANDE (Symptom Assessment in Dry Eye) questionnaire was a short questionnaire to evaluate both dry eye frequency and severity by using a 100 mm VAS. The subject symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assess both severity and frequency of symptoms. For the assessment, the subjects marked on the 100 mm VAS line the point that they felt represented their perception of their current state. The VAS score was determined by measuring in millimeters from the left hand end of the line to the point that the subject marked. The SANDE scores was then evaluated for the 2 questions severity (0-100) and frequency (0-100), where 0 was the best condition and 100 marked the worst condition.
Measured: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Slit Lamp Examination (SLE) Values
The Slit Lamp Examination was used to examine the structures of the eye (eyelids, lashes, conjunctiva, cornea, lens, iris and anterior chamber) according to different scales: Eyelid - Meibomian glands (from 0-none to 3-severe), Eyelid - Erythema (from 0-none to 4-very severe), Eyelid - Oedema (from 0-none to 4-very severe), Lashes (0-normal 1-abnormal), Conjunctiva - Erythema (from 0-none to 3-severe), Conjunctiva - Oedema (from 0-none to 4-very severe), Lens (to 0-no opacification to 3-severe opacification), Iris (0-normal 1-abnormal), Anterior chamber inflammation (from 0-none to 3-severe), Cornea transparency (from 0-completely transparent to 4-complete cornea opacity), Cornea neovascularization (0-absence of vascularization to 4- neovascularization between 270° and 360°). The higher the score the worse the outcome. There was not a total score.
Measured: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in IOP (Intraocular Pressure)
The IOP (intraocular pressure) of the eye was determined by the balance between the amount of aqueous humor that the eye marked and ease with which it leaved the eye. IOP was performed using Goldmann applanation tonometry after the instillation of a topical anaesthetic. The Goldmann applanation tonometer measured the force necessary to flatten a corneal area of 3.06 mm diameter. At this diameter, the resistance of the cornea to flattening was counterbalanced by the capillary attraction of the tear film meniscus for the tonometer head. The IOP (in mm Hg) equals the flattening force (in grams) multiplied by 10. IOP was measured in both eyes after completion of all SLEs to avoid potential interference with the other evaluations. Both eyes were tested. Normal eye pressure was between 10 to 21 mmHg. High ocular pressure was greater than 21 mmHg.
Measured: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Corneal Sensitivity by Cochet-Bonnet Aesthesiometry
The Cochet-Bonnet aesthesiometer contained a thin, retractable, nylon monofilament that extended up to 6 cm in length. Variable pressure could be applied to the cornea by adjusting the monofilament length. The monofilament length ranged from 6 to 0.5 cm. As the monofilament length was decreased the pressure increased from 11 mm/gm to 200 mm/gm. Corneal sensation was measured in the affected eye(s) in the central area of the cornea using a Cochet Bonnet aesthesiometer before the instillation of any dilating or anesthetic eye drops. The length of the filament in cm at which the patient corneal sensation was observed for the tested area of the cornea was reported. With decreasing length of monofilament, the corneal touch threshold increased and the corneal sensitivity decreased. Therefore, decreasing the length of monofilament was proportional to decreased corneal sensitivity.
Measured: From baseline (Day 1 pre-dose) to Day 15±2 and Day 22±2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2017 (estimated)
- Study start17 Jun 2017
- Primary completion10 Aug 2017
- Study completion10 Aug 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Ocular DiscomfortStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Flavio Mantelli, MD-PhD, Study director, Dompé Farmaceutici S.p.A
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03031327
- Sponsor's protocol ID
- LUB0116MD
- Other IDs
- CIV-15-05-013553
- Status last verified
- Oct 2024
- First submitted
- 23 Jan 2017
- Last updated
- 6 Dec 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 2 Weeks, Randomized, Double-masked, Controlled Study to Assess Tolerability, Safety, Permanence on the Ocular Surface, Efficacy of Lubricin (20 and 50 μg/ml) vs Sodium Hyaluronate 0.18% in Ocular Discomfort Following Refractive Surgery.
- ClinicalTrials.gov ID
- NCT03031327
- Acronym / sponsor ID
- LUB0116MD
- Conditions
- Ocular Discomfort
- Keywords
- Ocular Discomfort Following Refractive Surgery, Refractive Surgery, sodium hyaluronate, HA, Vismed®, Lubricin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Dompé Farmaceutici S.p.AIndustry (pharma, biotech, devices)
- Study start
- 17 Jun 2017 (actual)
- Primary completion
- 10 Aug 2017 (actual)
- Study completion
- 10 Aug 2017 (actual)
- First posted
- 25 Jan 2017 (estimated)
- Results
- Posted 6 Dec 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study was to evaluate tolerability, safety, permanence on the ocular surface and efficacy of Lubricin (20 and 50 μg/mL) eye drops vs Sodium Hyaluronate (Vismed®) 0.18% eye drops in patients with ocular discomfort following refractive surgery.
Primary objectives:
- Tolerability using a Visual analogue scale (VAS) for dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia;
- Treatment-emergent adverse events (TEAEs), assessed throughout the study.
Secondary objectives:
- Ocular surface vital staining with Fluorescein (Oxford scale)
- Schirmer-I test (without anaesthesia);
- Permanence of Lubricin on the Ocular Surface Tear film break-up time (TFBUT);
- Best corrected distance visual acuity (BCDVA);
- SANDE questionnaire scores - discomfort improvement entity;
- SANDE questionnaire scores - discomfort improvement speed;
- Signs evaluated by Slit lamp examination (SLE) (blepharitis, eyelid hyperemia/oedema, lashes, conjunctiva hyperemia);
- Intraocular pressure (IOP) ;
- Corneal sensitivity by Cochet-Bonnet aesthesiometry.
All parameters were evaluated at V1 (Day 1 - Baseline), V2 (Day 15±2) and V3 (Day 22±2/ETV).
Detailed description
This study was a 2 week randomized (1:1:1), controlled, double-masked, parallel group, pre-market study to evaluate tolerability, safety, permanence on the ocular surface and efficacy of Lubricin (20 and 50 μg/mL) eye drops vs Sodium Hyaluronate (Vismed®) 0.18% eye drops in patients with ocular discomfort following refractive surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Lubricin 20µg/ml | Experimental | Device: Lubricin 20µg/mlLubricin 20µg/ml eye drops solution Test investigational device was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2. All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the "Study/Primary eye". If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as "Study/Primary eye". In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as "Study/Primary eye". The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable. After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2. |
| Lubricin 50µg/ml | Experimental | Device: Lubricin 50µg/mlLubricin 50µg/ml eye drops solution Test investigational device was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2. All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the "Study/Primary eye". If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as "Study/Primary eye". In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as "Study/Primary eye". The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable. After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2. |
| Sodium hyaluronate | Active comparator | Device: Sodium hyaluronate 0.18%Vismed® 0.18% Sodium hyaluronate (HA) eye drops Comparator was instilled t.i.d. (three times a day) approximately every 6 h, from day 1 to day 15±2. All the patients instilled their assigned IMD into both eyes, unless only one eye met the eligibility criteria. If just one eye met the eligibility criteria, that was identified as the "Study/Primary eye". If both eyes met the eligibility criteria, the worst one (highest VAS average score) was chosen as "Study/Primary eye". In the event that the mean VAS score was equal in both eyes, right eye was to be chosen as "Study/Primary eye". The investigator instilled the morning study dose on Day 1 then the patients self-instilled the drops at home/site, as applicable. After the end of the treatment period, all the subjects could use any ocular topical treatment allowed, including other artificial tears/lubricants as prescribed by the treating physician, from day 15±2 to day 21±2. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patients 18 years of age or older;
- Patients undergone ocular refractive surgery within 6 months from V1 - Day 1;
- Patients with ocular discomfort defined as SANDE score ≥ 30 at baseline;
- Average VAS score (dryness, foreign body sensation, burning/stinging, itching, pain, stick feeling, blurred vision and photophobia) ≥ 25 mm;
- Best corrected distance visual acuity (BCDVA) score ≥ 0.1 decimal units in both eyes at the time of study enrolment;
Key exclusion criteria (16 listed)
- Patients with a severe Dry Eye condition (severity level 4 according to the Report of the International Dry Eye Workshop -DEWS, 2007);
- Best corrected distance visual acuity (BCDVA) score of < 0.1 decimal units in either eye at the time of study enrolment;
- Evidence of an active ocular infection in either eye;
- History or presence of ocular surface disorders other than ocular discomfort in either eye;
- Use of any ocular topical medication other than the study medications for the treatment of ocular diseases including artificial tears during the study period;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lubricin 20µg/mlLubricin 20µg/ml eye drops | Device | Lubricin 20µg/ml |
| Lubricin 50µg/mlLubricin 50µg/ml eye drops | Device | Lubricin 50µg/ml |
| Sodium hyaluronate 0.18%Also: Vismed®Sodium hyaluronate (HA) 0.18% eye drops | Device | Sodium hyaluronate |
Primary outcome
Changes From Baseline (Day 1 Pre-dose) in Ocular Tolerability Using a Visual Analogue Scale (VAS)
Time frame: Day 1 (baseline = Visit 1) at pre-dose, 15, 30 min post-dose; Day 15±2 (= Visit 2) at pre-dose, 15, 30 min post-dose; Day 22±2 (= Visit 3)
A global ocular tolerability score was determined using a 100 mm Visual Analogue Scale (VAS) on which 0 meant no symptoms and 100 meant the worst possible discomfort. This evaluation was to be performed before any ophtalmic assessment at each scheduled visit. Specific ocular symptoms measured with the VAS included: foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia. The patients evaluated their symptoms using the VAS giving the value they were feeling from none to an extreme value. The VAS scale was a straight horizontal line of fixed length (100 mm). The ends were defined as extreme limits of the parameter.
Treatment-emergent Adverse Events (TEAEs) Assessed Throughout the Study
Time frame: From baseline (Day 1 - pre-dose) to day 22±2
TEAEs included all AEs occurring or worsening after the first dose of IMD. These comprise AEs during the treatment and follow-up period. For TEAE, the number of events was provided. At each visit (Visit 1 which took place at Day 1; Visit 2 which took place at day 15 ± 2; Visit 3, i.e. final visi FU, at Day 22 ± 2/ETV), patients could spontaneously report any physical or medical occurrence and the investigator or designee inquired about the occurrence of TEAEs by asking specific questions. Any untoward (unfavorable \& unintended) change in subject's medical conditions was to be reported as an AE. Changes in any protocol-specific ocular or systemic parameter evaluated during the study were to be reviewed by the investigator. In addition, each patient's response to any questionnaire was to be reviewed by the investigator. Any untoward (unfavorable and unintended) change in a protocol-specific parameter or questionnaire response clinically relevant was to be reported as an AE.
8 secondary outcomes
Change From Baseline in Ocular Surface Vital Staining With Fluorescein (Oxford Scale)
Time frame: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Schirmer-I Test (Without Anaesthesia)
Time frame: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Permanence of Lubricin on the Ocular Surface - Tear Film Break-up Time (TFBUT)
Time frame: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA) - ETDRS Score
Time frame: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in SANDE (Symptom Assessment in Dry Eye) Questionnaire Scores
Time frame: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Slit Lamp Examination (SLE) Values
Time frame: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in IOP (Intraocular Pressure)
Time frame: Day 15±2 (Visit 2); Day 22±2 (Visit 3)
Change From Baseline in Corneal Sensitivity by Cochet-Bonnet Aesthesiometry
Time frame: From baseline (Day 1 pre-dose) to Day 15±2 and Day 22±2
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Dec 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Ocular Discomfort
Recruiting
Treating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution
Dry Eye Disease (DED), Contact Lens Discomfort (CLD)
RecruitingPhase 2
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Not yet recruitingPhase 4
Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%
Dry Eye, Contact Lens Discomfort
Recruiting
Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg
Dry Eye
RecruitingPhase 4
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
Dry Eye
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Flavio Mantelli, MD-PhD study director
Dompé Farmaceutici S.p.A
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lubricin 20µg/ml, Lubricin 50µg/ml and Sodium hyaluronate 0.18% in people with Ocular Discomfort, run by Dompé Farmaceutici S.p.A at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Dec 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes From Baseline (Day 1 Pre-dose) in Ocular Tolerability Using a Visual Analogue Scale (VAS) (time frame: Day 1 (baseline = Visit 1) at pre-dose, 15, 30 min post-dose; Day 15±2 (= Visit 2) at pre-dose, 15, 30 min post-dose; Day 22±2 (= Visit 3)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2024.